Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multi-cohort study of HT001 (docetaxel polymeric micelles for injection) in advanced solid tumors
CTR20213207Phase 2Active
- Sponsor
- HitBio
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HT001 in esophageal cancer, head and neck squamous cell carcinoma (HNSCC), biliary cancer, sponsored by HitBio. Started Mar 2022; status: active.
02
Drugs
HT001
03
Conditions
esophageal cancerhead and neck squamous cell carcinoma (HNSCC)biliary cancer
Beyond the preview
Go deeper on CTR20213207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213207.